Next Article in Journal
Production and Bioactivity-Guided Isolation of Antioxidants with α-Glucosidase Inhibitory and Anti-NO Properties from Marine Chitinous Materials
Next Article in Special Issue
Detecting Differential Transcription Factor Activity from ATAC-Seq Data
Previous Article in Journal
In Vitro Anticandidal Activity and Mechanism of a Polyoxovanadate Functionalized by Zn-Fluconazole Complexes
Previous Article in Special Issue
Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview
Molecules 2018, 23(5), 1123; https://doi.org/10.3390/molecules23051123

Transcription Factors as Therapeutic Targets in Chronic Kidney Disease

Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan
*
Author to whom correspondence should be addressed.
Academic Editor: Sanda Takaomi
Received: 17 April 2018 / Revised: 5 May 2018 / Accepted: 7 May 2018 / Published: 9 May 2018
(This article belongs to the Special Issue Transcription Factors as Therapeutic Targets)
View Full-Text   |   Download PDF [1360 KB, uploaded 9 May 2018]   |  

Abstract

The growing number of patients with chronic kidney disease (CKD) is recognized as an emerging problem worldwide. Recent studies have indicated that deregulation of transcription factors is associated with the onset or progression of kidney disease. Several clinical trials indicated that regression of CKD may be feasible via activation of the transcription factor nuclear factor erythroid-2 related factor 2 (Nrf2), which suggests that transcription factors may be potential drug targets for CKD. Agents stabilizing hypoxia-inducible factor (HIF), which may be beneficial for renal anemia and renal protection, are also now under clinical trial. Recently, we have reported that the transcription factor Kruppel-like factor 4 (KLF4) regulates the glomerular podocyte epigenome, and that the antiproteinuric effect of the renin–angiotensin system blockade may be partially mediated by KLF4. KLF4 is one of the Yamanaka factors that induces iPS cells and is reported to be involved in epigenetic remodeling. In this article, we summarize the transcription factors associated with CKD and particularly focus on the possibility of transcription factors being novel drug targets for CKD through epigenetic modulation. View Full-Text
Keywords: chronic kidney disease (CKD); Nrf2; bardoxolone methyl; HIF; KLF4; renin–angiotensin system (RAS) chronic kidney disease (CKD); Nrf2; bardoxolone methyl; HIF; KLF4; renin–angiotensin system (RAS)
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Hishikawa, A.; Hayashi, K.; Itoh, H. Transcription Factors as Therapeutic Targets in Chronic Kidney Disease. Molecules 2018, 23, 1123.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top